Benzinga | Feb 10, 2021 06:15AM EST

HC Wainwright & Co. Maintains Buy on KalVista Pharmaceuticals, Raises Price Target to $48

HC Wainwright & Co. analyst Andrew Fein maintains KalVista Pharmaceuticals (NASDAQ:KALV) with a Buy and raises the price target from $30 to $48.